Medigen

Focus: Medigen is a biotechnology company founded in 2004 specializing in cancer and infectious disease vaccines with contract services capabilities, headquartered in Frederick, MD. The company maintains a diversified pipeline across oncology, infectious diseases, and vaccine development.

Oncology Infectious Diseases Vaccines

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About Medigen

AI assessmentNot Hiring

No open roles listed right now. Follow Medigen to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

7 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

EV71 vaccine

Enterovirus 71 Human

N/A

Magicell-NK contains NK cells suspended in 100 mL normal saline

Colon Cancer Stage I

Phase 1

Clinical Trials (1)

Help build intelligence for Medigen

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diverse pipeline with 30+ programs across high-impact areas (oncology, COVID-19, dengue, enterovirus) provides exposure to multiple therapeutic modalities and disease states
Early-stage programs (7 Phase 1/2 trials) suggest active R&D environment with potential for scientific contribution and career growth in emerging vaccine/immunotherapy space
Established infectious disease and cancer vaccine focus aligns with long-term public health demand and regulatory tailwinds

Watch Out For

Zero active job postings signals potential hiring freeze, restructuring, or organizational transition—major red flag for immediate employment prospects
Lack of disclosed financials, employee count, and funding data obscures company stability, burn rate, and likelihood of continued operations or acquisition

Generated by Claude from Medigen's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.